MSD Q2 2026 Financial Results Show KEYTRUDA QLEX, and LIPFENDRA Momentum
Merck posted $16.6 billion in Q2 2026 sales as LIPFENDRA won FDA approval and KEYTRUDA QLEX gained traction, even as a Terns acquisition charge drove a GAAP loss.
